Anthem Biosciences

Anthem Biosciences

772.05
-3.50
(-0.45%)
hide
Key Fundamentals
Add Ratio
Market Cap
43,359.10 Cr
EPS
8.07
PE Ratio
96.47
Dividend Yield
0.00 %
Industry
-
52 Week High
873.50
52 Week Low
701.90
PB Ratio
18.07
Debt to Equity
0.08
Sector
-
Analyst Rating and Forecast
- By Refinitiv from1 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy0.0 %
0.0 %
Hold
Hold+100.00 %
+100.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Three companies will see their share lock-in periods expire on Wednesday, October 15. Anthem BioSciences will have 8.9 million shares (2% of outstanding equity) become eligible for trading, with the stock gaining 8% since listing in July at ₹570 per share. Shringar House of Mangalsutra will see 3.6 million shares (4% of outstanding equity) become tradeable, with the stock currently trading around its listing price of ₹188.50. The company's ₹400 crore IPO was oversubscribed by 60 times. Dev Accelerator will have 5.2 million shares (6% of outstanding equity) eligible for trading, though the stock has declined 21% from its IPO price since listing in September. The end of lock-in periods makes shares eligible for trading but does not guarantee they will be sold in the open market.
positive
Anthem Biosciences shares have gained 46% since listing on July 21, with an 11% increase following strong June-quarter results announced on August 13. The drug discovery and manufacturing services company reported revenue growth of 59.5% year-on-year to ₹540.2 crore and net profit surge of 64.8% to ₹135.8 crore in the June quarter. The company is expanding capacity by 155 kilolitres to reach 425 kilolitres total by September 2025, with 54 kilolitres added in the June quarter. Two products received approval, increasing the commercial portfolio from 10 to 12. The company expects 20% annual revenue growth for FY26. Operating margin dropped to 38.1% from 39.2% due to share-based compensation charges of ₹4.4 crore. Anthem completed backward integration on a key molecule and is developing GLP-1 obesity and diabetes drugs as patents expire in multiple markets.
positive
Anthem Biosciences delivered consolidated revenue of INR 540 crores for the quarter ended June 30, 2025, representing strong year-on-year growth. The CRDM business contributed INR 452.7 crores while specialty ingredients generated INR 87.5 crores. EBITDA reached INR 214.3 crores with margins at 38%, and PAT was INR 135.8 crores with 24% margins. The company maintains a net cash position of INR 784.8 crores. Growth was driven by increased demand from commercial products across multiple customers. Two molecules moved from Phase 3 to commercial stage, expanding the commercial portfolio from 10 to 12 products. The company added 54 kiloliters of custom synthesis capacity in unit 2 during the quarter and plans to complete remaining expansions by calendar year end. Management expects to maintain historical growth rates of around 20% annually, though noted this was an exceptional quarter due to the lumpy nature of their business.
View more
Growth Rate
Revenue Growth
30.15 %
Net Income Growth
22.87 %
Cash Flow Change
198.49 %
ROE
-1.83 %
ROCE
13.75 %
EBITDA Margin (Avg.)
2.22 %

Quarterly Financial Results

Quarterly Financials
Jun 2024
Mar 2025
Jun 2025
Revenue
358
497
563
Expenses
218
288
349
EBITDA
140
209
214
Operating Profit %
36 %
40 %
35 %
Depreciation
19
30
27
Interest
4
1
2
Profit Before Tax
118
178
186
Tax
36
96
51
Net Profit
82
83
136
EPS in ₹
1.47
1.48
2.43

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
787
1,034
1,619
2,015
2,398
2,808
Fixed Assets
306
361
329
449
483
705
Current Assets
403
616
1,098
1,323
1,482
1,737
Capital Work in Progress
50
19
154
164
345
297
Investments
99
209
273
499
472
433
Other Assets
333
445
863
903
1,099
1,373
Total Liabilities
787
1,034
1,619
2,015
2,398
2,808
Current Liabilities
247
285
223
164
339
326
Non Current Liabilities
118
47
41
110
135
72
Total Equity
422
702
1,355
1,741
1,925
2,410
Reserve & Surplus
414
693
1,346
1,627
1,813
2,298
Share Capital
8
9
9
114
112
112

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
9
18
308
-6
-159
133
Investing Activities
-109
-196
-205
-376
-222
-152
Operating Activities
166
278
333
306
140
418
Financing Activities
-48
-63
181
64
-77
-134

Share Holding

% Holding
Dec 2024
Jul 2025
Promoter
77.23 %
76.88 %
FIIs
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
Government
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
Others
22.77 %
23.12 %
No of Share Holders
16
761

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Aug 2025 749.65 743.45

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201810 days ago
Closure of Trading WindowSep 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 15, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 08, 2025
Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Announcement Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Jul 21, 2025
Closure of Trading WindowJul 21, 2025
Appointment of Company Secretary and Compliance OfficerJul 21, 2025
Listing of Equity Shares of Anthem Biosciences LtdJul 21, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Mahindra Manulife Mid Cap Fund Direct - Growth
1.92%
384657
0.62%
1.89%
Axis Small Cap Fund Direct-Growth
0.05%
-229451
-0.08%
-0.07%
Axis ELSS Tax Saver Direct Plan-Growth
0.32%
139917
0.01%
0.04%
HDFC Manufacturing Fund Direct - Growth
0.92%
100000
0.00%
0.11%
360 ONE FlexiCap Fund Direct - Growth
0.59%
-90435
-0.43%
-0.36%
Mirae Asset Small Cap Fund Direct-Growth
0.20%
52954
0.16%
0.16%
Mirae Asset Flexi Cap Fund Direct - Growth
0.13%
40000
0.09%
0.10%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
1.51%
-37605
-0.91%
-1.74%
Bandhan Midcap Fund Direct-Growth
0.78%
20000
0.01%
0.24%
Axis Business Cycles Fund Direct-Growth
0.61%
18440
0.03%
0.08%
Quant Healthcare Fund Direct - Growth
6.70%
13554
-0.12%
0.77%
Kotak Healthcare Fund Direct - Growth
2.79%
13220
0.04%
0.34%
Groww Multicap Fund Direct-Growth
1.42%
7342
-0.05%
0.42%
Kotak MNC Fund Direct-Growth
0.80%
6036
-0.04%
0.04%
Union Large & Midcap Fund Direct - Growth
0.00%
-3446
-0.03%
-0.03%
Bandhan Aggressive Hybrid Fund Direct-Growth
0.79%
3111
-0.10%
-0.07%
Union ELSS Tax Saver Fund Direct-Growth
0.00%
-2023
-0.02%
-0.02%
Union Retirement Fund Direct - Growth
0.00%
-679
-0.03%
-0.03%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.23%
0
-0.01%
0.00%
PGIM India Flexi Cap Fund Direct-Growth
0.88%
0
-0.06%
0.21%
HDFC Business Cycle Fund Direct - Growth
3.50%
0
-0.28%
0.42%
HDFC Innovation Fund Direct-Growth
1.17%
0
-0.13%
-0.08%
Franklin India Mid Cap Fund Direct-Growth
0.26%
0
-0.02%
0.01%
HDFC MNC Fund Direct - Growth
3.89%
0
-0.30%
0.65%
HDFC Pharma And Healthcare Fund Direct - Growth
3.26%
0
-0.21%
0.30%

Technical Indicators

RSI(14)
Neutral
44.67
ATR(14)
Less Volatile
23.68
STOCH(9,6)
Neutral
56.86
STOCH RSI(14)
Neutral
59.18
MACD(12,26)
Bearish
-1.29
ADX(14)
Weak Trend
20.31
UO(9)
Bearish
54.77
ROC(12)
Downtrend And Accelerating
-0.69
WillR(14)
Neutral
-59.31